Impaired autophagy contributes to adverse cardiac remodeling in acute myocardial infarction

PLoS One. 2014 Nov 19;9(11):e112891. doi: 10.1371/journal.pone.0112891. eCollection 2014.

Abstract

Objective: Autophagy is activated in ischemic heart diseases, but its dynamics and functional roles remain unclear and controversial. In this study, we investigated the dynamics and role of autophagy and the mechanism(s), if any, during postinfarction cardiac remodeling.

Methods and results: Acute myocardial infarction (AMI) was induced by ligating left anterior descending (LAD) coronary artery. Autophagy was found to be induced sharply 12-24 hours after surgery by testing LC3 modification and Electron microscopy. P62 degradation in the infarct border zone was increased from day 0.5 to day 3, and however, decreased from day 5 until day 21 after LAD ligation. These results indicated that autophagy was induced in the acute phase of AMI, and however, impaired in the latter phase of AMI. To investigate the significance of the impaired autophagy in the latter phase of AMI, we treated the mice with Rapamycin (an autophagy enhancer, 2.0 mg/kg/day) or 3-methyladenine (3MA, an autophagy inhibitor, 15 mg/kg/day) one day after LAD ligation until the end of experiment. The results showed that Rapamycin attenuated, while 3MA exacerbated, postinfarction cardiac remodeling and dysfunction respectively. In addition, Rapamycin protected the H9C2 cells against oxygen glucose deprivation in vitro. Specifically, we found that Rapamycin attenuated NFκB activation after LAD ligation. And the inflammatory response in the acute stage of AMI was significantly restrained with Rapamycin treatment. In vitro, inhibition of NFκB restored autophagy in a negative reflex.

Conclusion: Sustained myocardial ischemia impairs cardiomyocyte autophagy, which is an essential mechanism that protects against adverse cardiac remodeling. Augmenting autophagy could be a therapeutic strategy for acute myocardial infarction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Animals
  • Autophagy* / drug effects
  • Cell Line
  • Glucose / metabolism
  • Male
  • Mice
  • Myocardial Infarction / pathology*
  • NF-kappa B / metabolism
  • Oxygen / metabolism
  • Rats
  • Sirolimus / pharmacology
  • Ventricular Remodeling* / drug effects

Substances

  • NF-kappa B
  • Glucose
  • Oxygen
  • Sirolimus

Grants and funding

This study was supported by grants from the National Natural Science Foundation of China (grant No. 81001436 to Dr. X Wu and grant No. 81173062 to Dr. J Luo), the Education Administration Research Foundation of Guangzhou City (grant No. 10A018G and 10A157 to Dr. X Wu), outstanding young scientist training program by Department of Education of Guangdong province (grant No. Yq2013134 to Dr. X Wu), and Science and Information Technology of Guangzhou (grant No. 12C22021631 to Dr. J Luo). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.